An official website of the United States government
Home
Name
Pertuzumab
Alternate Names
Omnitarg
Perjeta
R1273
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Cytostatic agent--tyrosine kinase inhibitor
Humanized monoclonal antibody
NSC Number
900005
Primary Site
Breast
Histology
None
Remarks
JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Pertuzumab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code pertuzumab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy.
FDA approved Perjeta June 8, 2012 to treat HER2-positive late-stage (metastatic) breast cancer.
Perjeta is also used in combination with trastuzumab and docetaxel for neoadjuvant treatment of patients with HER2-positive locally advanced, inflammatory, or early stage breast cancer (either TS >2cm or node positive) as part of a complete treatment regimen for early breast cancer.
FDA approved Perjeta June 8, 2012 to treat HER2-positive late-stage (metastatic) breast cancer.
Perjeta is also used in combination with trastuzumab and docetaxel for neoadjuvant treatment of patients with HER2-positive locally advanced, inflammatory, or early stage breast cancer (either TS >2cm or node positive) as part of a complete treatment regimen for early breast cancer.
Coding
This drug should be coded
